logo

Agios Pharmaceuticals, Inc. (AGIO)



Trade AGIO now with
  Date
  Headline
1/12/2020 8:06:42 PM Agios Expects To Have 4 Marketed Products In At Least 8 Indications, At Least 6 Molecules In Development In 2025
11/7/2019 9:57:55 PM Agios Prices Underwritten Public Offering Of 8.25 Mln Shares At $31.00/shr
10/9/2019 7:08:58 AM Agios To Present Data From AG-270 Phase 1 Dose-Escalation Study At AACR-NCI-EORTC International Conference
9/10/2019 7:05:23 AM Agios To Present Phase 3 ClarIDHy Study Data Of TIBSOV At ESMO
2/25/2019 7:20:06 AM Agios Pharma Presents Updated Data From Phase 1 Study Of Ivosidenib In Combination With Azacitidine
2/20/2019 7:05:15 AM Agios Announces FDA Acceptance Of SNDA For TIBSOVO
11/16/2018 7:07:03 AM Agios Pharma Presents Updated Data From Ongoing Phase 1 Study Of Single Agent AG-881 In Advanced Glioma
8/17/2018 4:10:51 AM New Drugs Approved In July
8/2/2018 7:21:05 AM Agios Q2 Net Loss $68.7 Mln Vs Loss Of $83.1 Mln Last Year
3/19/2018 7:08:24 AM Agios Pharma Announces Dosing Of First Patient In A Phase 1 Study Of AG-270
2/14/2018 7:09:43 AM Agios Pharma Posts Q4 Net Loss Of $88.28 Mln Or $1.81/share
1/18/2018 9:01:50 PM Agios Announces Pricing Of $475 Mln Public Offering Of Common Stock
  
 
>